**MUTUAL NON-DISCLOSURE AGREEMENT**

**MATTER NO.:** CIL-2022-003  
**DATED:** November 10, 2022

This Mutual Non-Disclosure Agreement ("Agreement") is entered into as of November 10, 2022 ("Effective Date"), by and between ChemInnovate Labs, LLC, a California limited liability company ("ChemInnovate"), and Advanced Materials Corporation, a Delaware corporation ("AMC") (each individually a "Party" and collectively the "Parties").

## RECITALS

WHEREAS, the Parties wish to explore a potential joint development project relating to biodegradable polymer compositions with enhanced UV stability (the "Purpose");

WHEREAS, in connection with the Purpose, each Party may disclose to the other certain confidential and proprietary information, including but not limited to technical data, formulations, and intellectual property;

WHEREAS, the Parties desire to maintain the confidentiality of such information in accordance with the terms set forth herein;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

## 1. DEFINITIONS

### 1.1 "Confidential Information" 
shall mean any and all non-public information disclosed by one Party (the "Disclosing Party") to the other Party (the "Receiving Party"), whether disclosed orally, in writing, or in any other form, including without limitation:

(a) Technical information, including but not limited to: chemical formulations, polymer compositions, synthesis procedures, analytical methods, test data, research results, technical know-how, and manufacturing processes;

(b) Intellectual property, including but not limited to: invention disclosures, patent applications (published or unpublished), trade secrets, and proprietary methodologies;

(c) Business information, including but not limited to: financial data, business plans, customer lists, supplier information, and strategic initiatives;

(d) Any other information that is marked as "Confidential," "Proprietary," or with similar designation, or that would reasonably be considered confidential given the nature of the information and circumstances of disclosure.

### 1.2 "Representatives" 
shall mean a Party's employees, officers, directors, advisors, consultants, or agents who have a legitimate need to know the Confidential Information for the Purpose.

## 2. CONFIDENTIALITY OBLIGATIONS

### 2.1 Protection of Confidential Information
Each Receiving Party agrees to:

(a) Maintain the confidentiality of all Confidential Information using the same degree of care it uses to protect its own confidential information of similar nature, but in no event less than reasonable care;

(b) Not disclose Confidential Information to any third party without the prior written consent of the Disclosing Party;

(c) Use the Confidential Information solely for the Purpose and for no other purpose whatsoever;

(d) Limit access to Confidential Information to those Representatives who have a legitimate need to know for the Purpose;

(e) Ensure that its Representatives are bound by written confidentiality obligations no less restrictive than those contained herein.

### 2.2 Chemical Safety and Handling
In accordance with applicable regulations, including but not limited to OSHA standards and EPA guidelines, any Confidential Information relating to chemical compositions shall be accompanied by appropriate Safety Data Sheets (SDS) and handling instructions.

## 3. EXCEPTIONS

The obligations set forth in Section 2 shall not apply to Confidential Information that:

(a) Is or becomes publicly available through no breach of this Agreement by the Receiving Party;

(b) Is rightfully received by the Receiving Party from a third party without breach of any confidentiality obligation;

(c) Is independently developed by the Receiving Party without use of or reference to the Confidential Information, as evidenced by written records;

(d) Was known to the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by written records;

(e) Is required to be disclosed by law, regulation, or court order, provided that the Receiving Party provides prompt written notice to the Disclosing Party and cooperates in any effort by the Disclosing Party to seek a protective order.

## 4. INTELLECTUAL PROPERTY

### 4.1 No License Grant
Nothing in this Agreement shall be construed as granting any rights, by license or otherwise, to any Confidential Information or any intellectual property rights of the Disclosing Party.

### 4.2 Ownership
All Confidential Information shall remain the sole property of the Disclosing Party. The Receiving Party acknowledges that no title to or ownership of the Confidential Information is transferred.

### 4.3 Joint Developments
Any improvements, modifications, or derivatives of the Confidential Information developed jointly by the Parties shall be addressed in a separate joint development agreement.

## 5. TERM AND TERMINATION

### 5.1 Term
This Agreement shall commence on the Effective Date and continue for a period of five (5) years, unless earlier terminated in accordance with Section 5.2.

### 5.2 Termination
Either Party may terminate this Agreement at any time upon thirty (30) days' written notice to the other Party.

### 5.3 Survival
The obligations of confidentiality set forth herein shall survive termination of this Agreement for a period of five (5) years from the date of termination.

## 6. RETURN OF MATERIALS

Upon written request by the Disclosing Party or upon termination of this Agreement, the Receiving Party shall promptly:

(a) Return all tangible materials containing or embodying Confidential Information;

(b) Destroy all copies, notes, or derivatives thereof in its possession or control;

(c) Provide written certification of compliance with this Section 6.

## 7. NO WARRANTY

ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS." THE DISCLOSING PARTY MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

## 8. REMEDIES

The Parties acknowledge that breach of this Agreement may cause irreparable harm for which monetary damages would be an inadequate remedy. Accordingly, the non-breaching Party shall be entitled to seek equitable relief, including injunction and specific performance, in addition to all other available remedies.

## 9. GENERAL PROVISIONS

### 9.1 Governing Law
This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to its conflict of law principles.

### 9.2 Entire Agreement
This Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all prior or contemporaneous agreements, whether written or oral.

### 9.3 Amendment
This Agreement may only be amended by a written instrument signed by authorized representatives of both Parties.

### 9.4 Assignment
Neither Party may assign this Agreement without the prior written consent of the other Party, except to a successor in connection with a merger, acquisition, or sale of substantially all assets.

### 9.5 Counterparts
This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first written above.

**CHEMINNOVATE LABS, LLC**

By: _________________________________  
Name: Dr. Robert Martinez  
Title: President  
Date: November 10, 2022

**ADVANCED MATERIALS CORPORATION**

By: _________________________________  
Name: Susan K. Thompson  
Title: Vice President, R&D  
Date: November 10, 2022

---

Prepared by:  
Sarah Chen, Esq.  
State Bar No. 287654  
Peninsula IP Partners  
2500 Sand Hill Road, Suite 200  
Palo Alto, CA 94025  
(650) 555-4102  
schen@peninsulaip.com 